» Articles » PMID: 20177800

Inhibitory Effects of Devil's Claw (secondary Root of Harpagophytum Procumbens) Extract and Harpagoside on Cytokine Production in Mouse Macrophages

Overview
Journal J Nat Med
Publisher Springer
Date 2010 Feb 24
PMID 20177800
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Successive oral administration (50 mg/kg) of a 50% ethanolic extract (HP-ext) of devil's claw, the secondary root of Harpagophytum procumbens, showed a significant anti-inflammatory effect in the rat adjuvant-induced chronic arthritis model. HP-ext dose-dependently suppressed the lipopolysaccharide (LPS)-induced production of inflammatory cytokines [interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha)] in mouse macrophage cells (RAW 264.7). Harpagoside, a major iridoid glycoside present in devil's claw, was found to be one of the active agents in HP-ext and inhibited the production of IL-1beta, IL-6, and TNF-alpha by RAW 264.7.

Citing Articles

Leaf extracts of eight selected southern African medicinal plants modulate pro-inflammatory cytokine secretion in LPS-stimulated RAW 264.7 macrophages.

Khumalo G, Loa-Kum-Cheung W, Van Wyk B, Feng Y, Cock I Inflammopharmacology. 2024; 32(2):1607-1620.

PMID: 38310564 PMC: 11006729. DOI: 10.1007/s10787-023-01420-9.


A Systemic Review on Nutraceutical Supplements used in the Management of Osteoarthritis.

Nooreen Z, Wal P, Summaiyya F Recent Adv Food Nutr Agric. 2024; 15(1):33-45.

PMID: 38258782 DOI: 10.2174/012772574X270405231102054920.


Analysis of the Anti-Inflammatory and Anti-Osteoarthritic Potential of Flonat Fast, a Combination of DC. ex Meisn., Roxb., L., Bromelain and Escin (), Evaluated in In Vitro Models of Inflammation Relevant to Osteoarthritis.

Quarta S, Santarpino G, Carluccio M, Calabriso N, Scoditti E, Siculella L Pharmaceuticals (Basel). 2022; 15(10).

PMID: 36297375 PMC: 9609228. DOI: 10.3390/ph15101263.


DNA Barcode Authentication of Devil's Claw Herbal Dietary Supplements.

Diaz-Silveira G, Deutsch J, Little D Plants (Basel). 2021; 10(10).

PMID: 34685813 PMC: 8540935. DOI: 10.3390/plants10102005.


From Bush Medicine to Modern Phytopharmaceutical: A Bibliographic Review of Devil's Claw ( spp.).

Brendler T Pharmaceuticals (Basel). 2021; 14(8).

PMID: 34451822 PMC: 8398729. DOI: 10.3390/ph14080726.


References
1.
Jang M, Lim S, Han S, Park H, Shin I, Kim J . Harpagophytum procumbens suppresses lipopolysaccharide-stimulated expressions of cyclooxygenase-2 and inducible nitric oxide synthase in fibroblast cell line L929. J Pharmacol Sci. 2003; 93(3):367-71. DOI: 10.1254/jphs.93.367. View

2.
Andersen M, Santos E, Seabra M, da Silva A, Tufik S . Evaluation of acute and chronic treatments with Harpagophytum procumbens on Freund's adjuvant-induced arthritis in rats. J Ethnopharmacol. 2004; 91(2-3):325-30. DOI: 10.1016/j.jep.2004.01.003. View

3.
Nakamura H, Shimizu M . Accelerated granuloma formation in adjuvant-induced arthritic rats and its modification by antirheumatic drugs. J Pharmacol Exp Ther. 1979; 211(1):20-5. View

4.
Huang T, Tran V, Duke R, Tan S, Chrubasik S, Roufogalis B . Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-kappa B activation. J Ethnopharmacol. 2005; 104(1-2):149-55. DOI: 10.1016/j.jep.2005.08.055. View

5.
Lanhers M, Fleurentin J, Mortier F, Vinche A, Younos C . Anti-inflammatory and analgesic effects of an aqueous extract of Harpagophytum procumbens. Planta Med. 1992; 58(2):117-23. DOI: 10.1055/s-2006-961411. View